Anixa Biosciences reports favorable safety and stable tumor lesions in first patient of CAR-T trial

Anixa Biosciences Inc

First patient treated in chimeric endocrine receptor T-cell (CAR-T) clinical trial shows favorable safety signals.
Imaging at one month post-treatment indicates tumor lesions are stable and not growing.
Patient appears to be doing well and will continue to be monitored; enrollment continues.
Data presented by inventor Dr. Jose Conejo-Garcia at AACR/Rivkin Ovarian Cancer Symposium.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.